SPATA2L

Across TCGA pan-cancer cohorts, SPATA2L RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated SPATA2L data layer compared with 4 for mutation status and 4 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher SPATA2L RNA is associated with worse overall survival. In most high-consensus cancer types, elevated SPATA2L expression acts as an unfavorable survival marker, although some lineages such as SCLC and KIRC show a favorable association.

UCS, ACC, and LGG are the cancer types where SPATA2L RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	OS	Tertile	II,III,IV	0.425	0.824	.003	74	view →
ACC	OS	Tertile	All	0.752	0.963	.002	45	view →
LGG	OS	Median	All	0.371	0.534	<.001	37	view →
BLCA	OS	Quartile	IV	0.354	0.606	.011	33	view →
SCLC	DFS	Median	All	0.444	0.165	.002	31	view →
LIHC	OS	Tertile	All	0.565	0.796	.006	29	view →
KIRC	DFS	Tertile	All	0.874	0.731	.006	24	view →
KIRP	OS	Quartile	All	0.989	0.907	.008	22	view →
LAML	DFS	Median	All	0.377	0.543	.012	18	view →
READ	DFS	Median	All	0.811	0.374	.006	17	view →
PAAD	OS	Quartile	All	0.613	0.215	<.001	15	view →
DLBC	DFS	Median	III,IV	0.140	0.917	.010	15	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

SPATA2L–UCS (OS)

Open the UCS breakdown →